China Health Group Inc. announced that Mr. Guo Tong has been appointed as an independent non-executive Director with effect from 14 April 2023. Mr. Guo, aged 55, is currently the Vice Chairman of the Clinical Trials Committee and Data Science Working Group Leader of the China Pharmaceutical Innovation and Research Development Association; a lecture instructor of the Master's Program in Health Leadership at Tsinghua University Medical College; a former member of the DIA China Advisory Board, an expert in big data and artificial intelligence, and a conference convener; and an external supervisor of master's degree students at China Pharmaceutical University. Mr. Guo has more than 20 years of experience in biostatistics, clinical operations, and business management in China and global pharmaceutical companies, and has led the statistical design and analysis of several global multi-center clinical trials, and has extensive research experience in clinical trial design and analysis, real-world research, medical big data and artificial intelligence applications.

Mr. Guo holds a master's degree in biostatistics and a PhD from McGill University, Canada. Mr. Guo has entered into a service agreement with the Company for a term of three years from 14 April 2023. The service agreement may be terminated in accordance with the provisions in the service agreement by either party giving to the other party not less than three months' written notice.

He is also subject to retirement by rotation and re-election at the general meetings of the Company. The Board also announced that with effect from 14 April 2023, Mr. Guo has been appointed as a member of the remuneration committee of the Board, a member of the audit committee of the Board and a member of the nomination committee of the Board.